NRI Share Price

Open 5.20 Change Price %
High 5.25 1 Day -0.03 -0.58
Low 5.15 1 Week -0.04 -0.77
Close 5.17 1 Month -0.28 -5.14
Volume 3100 1 Year -0.93 -15.25
52 Week High 8.35
52 Week Low 5.14
NRI Important Levels
Resistance 2 5.26
Resistance 1 5.22
Pivot 5.19
Support 1 5.12
Support 2 5.08
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
TBE 0.03 0.00%
RY 93.47 -0.20%
RY 93.47 -0.20%
BBD-B 2.11 -4.09%
NSU 3.03 -2.88%
More..
TSE Canada Top Gainers Stocks
TVI 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
PWC 0.10 25.00%
PWC 0.10 25.00%
IMP 0.10 25.00%
IMP 0.10 25.00%
IMP 0.10 25.00%
AVP 0.07 16.67%
More..
TSE Canada Top Losers Stocks
GBV 0.46 -24.59%
ANX 0.06 -14.29%
ANX 0.06 -14.29%
CTU-A 0.19 -9.52%
ONC 0.79 -9.20%
ONC 0.79 -9.20%
CCO 13.09 -8.33%
CCO 13.09 -8.33%
CCO 13.09 -8.33%
SLR 1.02 -7.27%
More..

Nuvo Research, Inc. (TSE: NRI)

NRI Technical Analysis 5
As on 28th Apr 2017 NRI Share Price closed @ 5.17 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 6.27 & Strong Sell for SHORT-TERM with Stoploss of 5.55 we also expect STOCK to react on Following IMPORTANT LEVELS.
NRI Target for April
1st Target up-side 6.07
2nd Target up-side 6.45
3rd Target up-side 6.82
1st Target down-side 5.01
2nd Target down-side 4.63
3rd Target down-side 4.26
NRI Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.nuvoresearch.com
NRI Address
NRI
7560 Airport Road
Unit 10
Mississauga, ON L4T 4H4
Canada
Phone: 905-673-6980
Fax: 905-673-1842
NRI Latest News
Nuvo Pharmaceuticals (NRI) EPS Estimated At $0.17; Biotest AG (ETR:BIO) Had 4 ...   Bibeypost.com   - 28th Apr 17
Research Reports Initiated on Healthcare Stocks: Valeant Pharma, Knight ...   Yahoo Finance   - 24th Apr 17
BRIEF-Nuvo Pharmaceuticals enters into license agreement with Sayre Therapeutics   Reuters   - 28th Mar 17
Nuvo Pharmaceuticals™ Inc. Appoints Jesse Ledger as President   PR Newswire (press release)   - 16th Nov 16
New CFOs for Cipher and Nuvo   Pharmaceutical Executive (press release) (registration) (blog)   - 06th Sep 16
Nuvo Pharmaceuticals™ Inc. Announces Pennsaid 2% Phase 3 Trial to Support ...   PR Newswire (press release)   - 13th Jul 16
Nuvo Pharmaceuticals™ Inc. Announces Results from European Ankle Sprain Study ...   PR Newswire (press release)   - 07th Mar 16
Nuvo Research® Inc. Completes Reorganization into Two Publicly Traded Companies   PR Newswire (press release)   - 01st Mar 16
Nuvo Research® Reports Topline Results of Phase 2 Trial of WF10™ for the ...   PR Newswire (press release)   - 21st Dec 15
Nuvo Research® Provides Update on Pennsaid® 2% Phase 3 Clinical Trial   PR Newswire (press release)   - 03rd Dec 15
Interactive Technical Analysis Chart Nuvo Research, Inc. ( NRI TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Nuvo Research, Inc.
NRI Business Profile
Nuvo Research Inc., a specialty pharmaceutical company, researches, develops, and commercializes pharmaceutical products in Europe, Asia, and South America. The company focuses on the development and commercialization of topically delivered pain products. Its topical pain products include Pennsaid, a non-steroidal anti-inflammatory drug that is used to treat the signs and symptoms associated with knee osteoarthritis; Pennsaid 2%, a follow-on product to Pennsaid for the treatment of pain of knee osteoarthritis; Synera, a topical patch that provides local dermal analgesia for superficial venous access and superficial dermatological procedures; and Pliaglis, a topical local anaesthetic cream, which provides local dermal anaesthesia on intact skin prior to superficial dermatological procedures, such as dermal filler injection, pulsed dye laser therapy, facial laser resurfacing, and laser-assisted tattoo removal. The company’s immunology products comprise WF10, a solution of OXO-K993 that focuses on supporting the immune system; and Oxoferin, a diluted form of WF10, which is a topical wound healing agent. The company was formerly known as Dimethaid Research Inc. and changed its name to Nuvo Research Inc. in September 2005. The company was founded in 1983 and is based in Mississauga, Canada.